On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...

The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...

British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant ...

Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...

The approval was based on results from the TROPION-Breast01 Phase III trial.

FDA approves AstraZeneca's Datroway, reducing breast cancer progression risk by 37% per TROPION-Breast01 trial results. Datroway's safety profile remains consistent, with 4.2% ILD rate ...

Tokyo: Daichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the ...